NetraMark Holdings Inc. (AIAI.CN) Aktuelle Nachrichten und Schlagzeilen zu Aktien – Yahoo Finanzen

NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING

NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV), a leader in generative AI software in clinical trial analysis, presents data demonstrating that its TAP™ scale for discovering placebo response personas using the Company’s NetraAI technology can help better characterize placebo and drug responders, making it a powerful tool for trial design and patient selection strategies. Dr. Joseph Geraci, PhD, Founder, Chief Scientific Officer of